Go Pro
→ Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid (From Altimetry) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$344.96
+0.9%		$343.58
$158.08
▼
$382.54
$10.39B0.54263,860 shs222,494 shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$115.81
+0.3%		$114.77
$51.47
▼
$130.05
$10.15B1.96670,362 shs841,718 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$513.21
+0.0%		$527.49
$393.61
▼
$615.00
$11.99B-0.98210,227 shs219,335 shs
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$41.99
-2.6%		$47.12
$35.93
▼
$83.12
$3.08B0.89718 shs100 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+0.94%+1.83%-3.15%-7.33%+112.94%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
+0.29%-2.25%-8.55%+7.11%+120.59%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+0.04%-3.97%+0.21%+0.11%+20.23%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
-2.59%-2.35%-18.95%-2.10%-43.26%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$344.96
+0.9%		$343.58
$158.08
▼
$382.54
$10.39B0.54263,860 shs222,494 shs
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$115.81
+0.3%		$114.77
$51.47
▼
$130.05
$10.15B1.96670,362 shs841,718 shs
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$513.21
+0.0%		$527.49
$393.61
▼
$615.00
$11.99B-0.98210,227 shs219,335 shs
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$41.99
-2.6%		$47.12
$35.93
▼
$83.12
$3.08B0.89718 shs100 shs
(Almost) Everything You Need To Know About The EV Market Cover
(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
+0.94%+1.83%-3.15%-7.33%+112.94%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
+0.29%-2.25%-8.55%+7.11%+120.59%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
+0.04%-3.97%+0.21%+0.11%+20.23%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
-2.59%-2.35%-18.95%-2.10%-43.26%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2.92
Moderate Buy$377.209.35% Upside
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
2.88
Moderate Buy$133.2115.02% Upside
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
2.78
Moderate Buy$710.2038.38% Upside
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
2.27
HoldN/AN/A

Current Analyst Ratings Breakdown

Latest ZLDPF, MDGL, KRYS, and KYMR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/24/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$704.00
9/24/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
The Goldman Sachs Group, Inc. logo
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$441.00
9/23/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight$140.00
9/23/2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
Citigroup Inc. logo
Citigroup
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageOutperform ➝ Buy$725.00
9/22/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Stifel Nicolaus logo
Stifel Nicolaus
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$132.00 ➝ $152.00
9/21/2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$392.00 ➝ $400.00
9/14/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$123.00 ➝ $144.00
9/11/2026
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeStrong Sell ➝ Hold
9/10/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Wolfe Research logo
Wolfe Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradePeer Perform ➝ Outperform$180.00
9/8/2026
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/31/2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
Guggenheim logo
Guggenheim
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$135.00 ➝ $170.00
(Data available from 9/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$389.13M26.24$7.17 per share48.13$42.06 per share8.20
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
$39.21M245.59N/AN/A$19.42 per share5.96
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
$958.40M12.37N/AN/A$26.54 per share19.34
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$1.40B2.15$13.46 per share3.12$31.61 per share1.33
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$204.83M$7.9843.2337.66N/A54.82%19.34%17.65%11/2/2026 (Estimated)
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$311.35M-$3.24N/AN/AN/A-285.33%-21.22%-19.21%11/3/2026 (Estimated)
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$288.28M-$12.89N/A92.47N/A-25.32%-56.65%-25.53%11/3/2026 (Estimated)
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
$977.29M$6.036.9616.47N/A58.86%18.53%17.14%11/12/2026 (Estimated)

Latest ZLDPF, MDGL, KRYS, and KYMR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
-$0.7126-$0.62+$0.0926-$0.62$32.78 million$65.00 million
8/3/2026Q2 2026
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
$1.70$1.79+$0.09$1.79$120.93 million$119.22 million
7/30/2026Q2 2026
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
-$2.68-$1.99+$0.69-$1.99$352.13 million$364.25 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/AN/AN/AN/AN/A
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/AN/AN/AN/AN/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
N/AN/AN/AN/AN/A
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
N/A
8.32
7.96
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
10.34
10.34
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
0.65
3.20
2.94
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
0.02
37.17
37.17

Institutional Ownership

CompanyInstitutional Ownership
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
86.29%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
N/A
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
98.50%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/A

Insider Ownership

CompanyInsider Ownership
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
13.10%
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
15.98%
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
17.60%
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
29529.60 million25.72 millionOptionable
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
27383.15 million69.86 millionOptionable
Madrigal Pharmaceuticals, Inc. stock logo
MDGL
Madrigal Pharmaceuticals
91523.10 million19.04 millionOptionable
Zealand Pharma A/S stock logo
ZLDPF
Zealand Pharma A/S
34071.53 millionN/ANot Optionable

Recent News About These Companies

Zealand Pharma A/S (OTCMKTS:ZLDPF) Stock Rated "Hold" by Wall Street Brokerages
 |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31048540
Zealand Pharma's short bowel syndrome drug wins backing from EU panel
September 18, 2026  |  reuters.comhttps://www.reuters.com/business/healthcare-pharmaceuticals/zealand-pharmas-short-bowel-syndrome-drug-wins-backing-eu-panel-2026-09-18/
Zealand Pharma: A Play On Medicine Discovery, But Too Expensive Right Now
September 9, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4944292-zealand-pharma-a-play-on-medicine-discovery-but-too-expensive-right-now
Zealand Pharma - Transactions related to share buy-back program (week 34, 2026)
August 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-34-2026-1036487042
Zealand Pharma – Notification of holding of treasury shares
August 24, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma-notification-of-holding-of-treasury-shares-1036487049
Zealand Pharma A/S
August 20, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/zldpf/company-people
Zealand Pharma - Transactions related to share buy-back program (week 33, 2026)
August 17, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-33-2026-1036466637
Zealand Pharma A/S (ZLDPY) Q2 2026 Earnings Call Transcript
August 13, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4936354-zealand-pharma-a-s-zldpy-q2-2026-earnings-call-transcript
Zealand Pharma A/S (ZLDPF) Surpasses Q2 Earnings and Revenue Estimates
August 13, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2973999/zealand-pharma-a-s-zldpf-surpasses-q2-earnings-and-revenue-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2973999
Zealand Pharma’s New Psoriasis Trial Sets Early Stage for ZP9830
July 29, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zealand-pharmas-new-psoriasis-trial-sets-early-stage-for-zp9830?utm_source=marketbeat.com&utm_medium=referral
Zealand Pharma Advances First-in-Human Obesity Drug Trial With ZP6590
July 24, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/zealand-pharma-advances-first-in-human-obesity-drug-trial-with-zp6590?utm_source=marketbeat.com&utm_medium=referral
Zealand Pharma - Transactions related to share buy-back program (week 28, 2026)
July 13, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-28-2026-1036319087
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
July 6, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-27-2026-1036300031
Total number of shares and voting rights in Zealand Pharma as of June 30, 2026
June 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/total-number-of-shares-and-voting-rights-in-zealand-pharma-as-of-june-30-2026-1036288061
Zealand Pharma major shareholder announcement: The Capital Group Companies, Inc.
June 30, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma-major-shareholder-announcement-the-capital-group-companies-inc-1036288056
Zealand Pharma - Transactions related to share buy-back program (week 26, 2026)
June 29, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-26-2026-1036283224
Zealand Pharma - Transactions related to share buy-back program (week 25, 2026)
June 22, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-25-2026-1036265764
Zealand Pharma stock suffered its two worst days on record. Here's what's next for the weight loss drugmaker
June 19, 2026  |  cnbc.comhttps://www.cnbc.com/2026/06/19/zealand-pharma-stock-weight-loss-drugmaker-novo-lilly.html
Zealand Pharma - Transactions related to share buy-back program (week 24, 2026)
June 15, 2026  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/zealand-pharma---transactions-related-to-share-buy-back-program-week-24-2026-1036249982
Drugmakers race to find a place in the next wave of obesity drugs
June 13, 2026  |  cnbc.comhttps://www.cnbc.com/2026/06/13/glp-1s-lilly-novo-pfizer-look-to-new-weight-loss-drugs.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Krystal Biotech stock logo

Krystal Biotech NASDAQ:KRYS

$344.96 +3.21 (+0.94%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$348.36 +3.40 (+0.99%)
As of 06:38 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Kymera Therapeutics stock logo

Kymera Therapeutics NASDAQ:KYMR

$115.81 +0.34 (+0.29%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$116.00 +0.19 (+0.16%)
As of 04:09 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Madrigal Pharmaceuticals stock logo

Madrigal Pharmaceuticals NASDAQ:MDGL

$513.21 +0.19 (+0.04%)
Closing price 09/24/2026 04:00 PM Eastern
Extended Trading
$513.92 +0.70 (+0.14%)
As of 09/24/2026 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

Zealand Pharma A/S stock logo

Zealand Pharma A/S OTCMKTS:ZLDPF

$41.99 -1.12 (-2.59%)
As of 09/24/2026 01:15 PM Eastern

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon that is in Phase III clinical trials for treating congenital hyperinsulinism. The company is also developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas